Latest Evidence-Based Insights on Weight Management and Healthy Living

Apple cider vinegar weight loss claims deflated: On September 24, 2025, the British Medical Journal retracted a widely cited 2024 clinical trial that asserted apple cider vinegar (ACV) could help overweight individuals shed significant weight. This retraction challenges popular wellness narratives, especially in regions like India where ACV has been heavily promoted as a natural weight loss aid.

Oral weight loss drug shows promising effectiveness: A recent global clinical trial involving over 3,100 adults with obesity demonstrated that patients taking orforglipron, an oral GLP-1 receptor agonist, lost up to 12% of their body weight. Published in the New England Journal of Medicine on September 17, 2025, this pill formulation does not require cold storage, potentially enhancing accessibility worldwide compared to traditional injectable GLP-1 medications.

Genetic factors influence GLP-1 weight loss outcomes: Cleveland Clinic research published on September 23, 2025, identified that genetic variations in the Neurobeachin gene dramatically affect weight loss success using GLP-1 medications. Individuals with genetic profiles deemed "responsive" were up to 82% more likely to experience significant weight loss, whereas those with "non-responsive" profiles had up to a 50% chance of poor response, underscoring the promise of personalized medicine approaches.

Mediterranean diet linked to improved gum health and reduced inflammation: A study from King's College London, published September 15, 2025, found that patients following a Mediterranean-style diet—rich in plant-based foods like vegetables, olive oil, and nuts—showed significantly lower blood levels of inflammatory markers Interleukin-6 (IL-6) and C-reactive protein (CRP) and better overall periodontal health compared to those frequently consuming red meat. This highlights additional benefits of Mediterranean eating patterns beyond cardiovascular health.

Pharmacists playing vital roles in optimizing GLP-1 therapies: New guidance published on September 24, 2025, emphasizes the expanding role of pharmacists in facilitating effective GLP-1 management. For example, oral semaglutide (Rybelsus) offers 100% bioavailability relative to injectables but requires administration on an empty stomach followed by a 30-minute wait before eating or taking other medications. Pharmacist counseling is pivotal to adherence and maximizing weight loss outcomes.

Sources

• https://www.ndtv.com/health/acv-weight-loss-hype-deflated-bmj-retracts-key-apple-cider-vinegar-study-9333035
• https://www.fingerlakes1.com/2025/09/24/pill-version-of-weight-loss-drug-shows-strong-results/
• https://newsroom.clevelandclinic.org/2025/09/23/gene-could-impact-weight-loss-using-glp-1-study-finds
• https://www.sciencedaily.com/releases/2025/09/250915202841.htm
• https://www.pharmacytimes.com/view/the-pharmacist-s-expanding-indispensable-role-in-optimizing-glp-1-management-and-patient-outcomes